Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the United States Patent and Trademark Office has issued two patents to Aduro related to the activation of the STING (Stimulator of Interferon Genes) Pathway.
A team of researchers from Chongqing University and the National Center for Nanoscience and Technology, both in China, has developed a sensor that is able to translate eye muscle movement into electrical signals that can be used to type or control an external device.
For the third time this spring, business advocates succeeded in persuading the U.S. Supreme Court to limit forum-shopping by tightening jurisdictional rules that determine where corporate defendants can be sued. In Bristol-Myers Squibb v. Superior Court of California, the court sided with the pharmaceutical company in its battle against a class action brought in California by injured users of Plavix, a blood-thinning drug, even though many of the plaintiffs had little or no connection to the
China’s State Intellectual Property Office, or SIPO, announced that it will grant the University of California, in conjunction with the University of Vienna and Emmanuelle Charpentier, a patent for its CRISPR gene-editing technology. China’s decision comes amidst a long battle between the UC and the Broad Institute over intellectual property rights for the CRISPR technology.
As the commercial drone market expands at an accelerating rate, so does the risk of malicious use of these devices and the need to successfully detect and take counter measures. This is the focus of the most recent PureTech Systems patent approval.
The Windows phone in the patent has a folding screen that would allow it to be used like a tablet, and comes with a mysterious 360-degree mode. While many have discussed the possibility of Windows 10 Mobile being killed off, Microsoft has always denied this. The company has continued to support the platform. Recent events have also supported this claim, including hints of a return to making mobile hardware. A Windows patent shows us how Microsoft envisions the smartphone of the future.
LegoChem Biosciences (“LCB”), a biopharmaceutical company focusing on the research & development of ADCs, based in Daejeon South Korea, announced today that the Company was awarded U.S. Patent No. 14517616, entitled “ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE.”
Ethics lawyers raise alarm over constitutional violation if president given special treatment in quickly securing 38 new trademarks to develop potential businesses. China has granted preliminary approval for 38 new Trump trademarks, paving the way for Donald Trump and his family to potentially develop a host of branded businesses from hotels to insurance to bodyguard and escort services.
Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice.
BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company, announced that two important new patents were granted extending patent protection around all three of its FDA approved products, Belbuca (buprenorphine) buccal film, Bunavail (buprenorphine and naloxone) buccal film, and Onsolis (fentanyl buccal soluble film), further strengthening BDSI's overall intellectual property position.
Cleveland HeartLab Inc. announces that a new patent U.S. Patent No. 9,575,065 for Myeloperoxidase (MPO) testing has been issued.
Soligenix, announces that its proprietary formulation of synthetic hypericin has been granted a European patent for the treatment of psoriasis. Synthetic hypericin, the active ingredient in SGX301, completed a Phase 2 clinical study demonstrating significant improvement in both Cutaneous T-cell lymphoma (CTCL) and psoriasis.
Emmaus announces the issuance of patent application number 2014-542296, by the Japanese Patent Office for the use of its lead investigative product, pharmaceutical grade L-glutamine (PGLG), for the treatment of diabetes.
Mithra Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for U.S. Application 14/238,310, a patent that covers the use of Estetrol (E4) as an emergency contraceptive.
Knopp Biosciences LLC has received United States Patent 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils.”
The United States Patent and Trademark Office has granted Verseon, US Patents 9,533,967 and 9,533,970, which cover various aspects of multiple families of compounds that were designed by the Company for its drug programs.
Intellipharmaceutics International Inc. announces that the U.S. Patent 9,522,119 and Canadian Patent 2,910,865 were issued by the USPTO and the CIPO in respect of “Compositions and Methods for Reducing Overdose”.
A published patent application for Nintendo’s upcoming Switch console describes plans for a potential head-mounted display accessory that holds the system's tablet-style screen in virtual reality-style housing.
Egalet Corporation announces that the USPTO has issued patent number 9,498,446 covering Egalet's proprietary Guardian Technology abuse-deterrent products which contain a matrix and an exterior shell including Phase 3 product candidate, Egalet002.
Shelfbucks Inc., the number one in-store retail merchandising optimization platform, announced it has acquired 24 granted patents that cover technologies used to measure execution, compliance and performance of in-store merchandising displays.
A patent Application published by Apple reveals that the company has been actively investigating a hinged iPhone format, with designs calling for a flexible metal-backed OLED display capable of being folded in half.
Apple has a new patented invention, and it is an advanced device that would be incorporated into a set of earbuds or headsets and the device is capable of collecting important data like body temperature and heart rate, among others.
Absorption Systems, announces the issuance of a U.S. patent for its unique In Vitro Dissolution Absorption System (IDAS2) technology, which enables the simultaneous evaluation of drug dissolution and absorption in various dosage forms, including tablets, capsules, and pre-formulations.
Intec Pharma Ltd., announces that the State Intellectual Property Office of the People’s Republic of China (SIPO) has granted a Chinese patent for an Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa.
Vanda Pharmaceuticals Inc. announces that they had entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc. to resolve Vanda's patent litigation against Taro regarding Taro's Abbreviated New Drug Application seeking approval of its generic version of Vanda's Fanapt (iloperidone).
U.S. Patent & Trademark Office (PTO) granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the sole unexpired patent listed as covering Janssen's ZYTIGA drug in the Food & Drug Administration's Orange Book.